Bolt Biotherapeutics (BOLT) Short Interest Ratio & Short Volume

Short interest is the volume of Bolt Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 66,000 shares of BOLT short. 0.26% of Bolt Biotherapeutics' shares are currently sold short. Learn More on Bolt Biotherapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.26% of Bolt Biotherapeutics' floating shares are currently sold short.

Bolt Biotherapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 66,000 shares, a drop of 44.8% from the previous total of 119,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Bolt Biotherapeutics currently has issued a total of 38,270,000 shares. Some of Bolt Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Bolt Biotherapeutics currently has a public float of 25,810,000 shares.

0.26% of Bolt Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Bolt Biotherapeutics: Agenus Inc. (13.16%), Fortress Biotech, Inc. (11.97%), SAB Biotherapeutics, Inc. (0.79%), Curis, Inc. (1.84%), Molecular Templates, Inc. (4.97%), Amgen Inc. (1.64%), Vertex Pharmaceuticals Incorporated (1.75%), Gilead Sciences, Inc. (1.43%), Regeneron Pharmaceuticals, Inc. (1.68%), Alnylam Pharmaceuticals, Inc. (2.87%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling BOLT is an investing strategy that aims to generate trading profit from Bolt Biotherapeutics as its price is falling. BOLT shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Bolt Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BOLT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BOLT, twice per month. The most recent reporting period available is October, 31 2024.